The hepatoprotective effects of ACTIValoe
®N-931 complex, a mixture of
Aloe vera and
Silybum marianum, against acute and chronic carbon tetrachloride (CCl
4)-induced liver injuries were investigated. Acute hepatotoxicity was induced by intraperitoneal injection of CCl
4 (50 μl/kg), and ACTIValoe
®N-931 complex at 85, 170, and 340 mg/kg was administered orally 48, 24, and 2 h before and 6 h after injection of CCl
4. Hepatotoxicity was assessed 24 h after CCl
4 treatment. Liver fibrosis was induced by intraperitoneal injection of CCl
4 for 8 weeks (0.5 ml/kg, twice per week), and mice were treated with ACTIValoe
®N-931 complex at 85, 170, or 340 mg/kg once a day (p.o.). In both acute hepatotoxicity and liver fibrosis, serum aminotransferase levels and lipid peroxidation were increased and the hepatic glutathione content was decreased. These changes were prevented by ACTIValoe
®N-931 complex. The ACTIValoe
®N-931 complex attenuated the increase in tumor necrosis factor-α (
TNF-α), and inducible nitric oxide synthase (
iNOS), and cyclooxygenase-2 (
COX-2), mRNA expressions in acute hepatotoxicity. In antifibrotic experiments, tissue inhibitor of metalloprotease-1 (
TIMP-1) mRNA expression was attenuated by treatment with ACTIValoe
®N-931 complex. The ACTIValoe
®N-931 complex decreased the hepatic hydroxyproline content and the transforming growth factor-beta1 levels. Our results suggest that the ACTIValoe
®N-931 complex has hepatoprotective effects in both acute and chronic liver injuries induced by CCl
4.
View full abstract